Archon Biosciences has emerged from stealth mode, announcing a successful $20 million Series A funding round to advance its novel AI-driven Antibody Cage technology. Developed in the Nobel Prize-winning laboratory of David Baker, this innovative class of biologic medicines, known as Antibody Cages (AbCs), combines traditional antibodies with advanced protein structures designed through artificial intelligence. The technology aims to enhance target engagement and address unmet medical needs. Additionally, the integration of AI in drug discovery is significantly revolutionizing the field, streamlining processes and reducing costs, as highlighted by NVIDIA's recent blog. The ongoing advancements in AI are also transforming healthcare by improving diagnostics and personalizing treatment plans for patients, as showcased in various discussions and forums focused on AI's role in healthcare.